anti-F8� antibody product blog
Tags: Antibody; Monoclonal Antibody; anti-F8� antibody;
The F8� n/a (Catalog #MBS2544423) is an Antibody produced from Rabbit and is intended for research purposes only. The product is available for immediate purchase. The Rabbit anti Human�F8� Monoclonal Antibody reacts with Human and may cross-react with other species as described in the data sheet. MyBioSource\'s F8� can be used in a range of immunoassay formats including, but not limited to, ELISA (EIA).ELISA: 0.1-0.2 mug/mL. This antibody can be used at 0.1-0.2 mug/mL with the appropriate secondary reagents to detect Human FVIII. The detection limit for Human FVIII is approximately 0.078ng/well. Researchers should empirically determine the suitability of the F8� n/a for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process.
The F8� n/a product has the following accession number(s) (GI #335704). Researchers may be interested in using Bioinformatics databases such as those available at The National Center for Biotechnology Information (NCBI) website for more information about accession numbers and the proteins they represent. Even researchers unfamiliar with bioinformatics databases will find the NCBI databases to be quite user friendly and useful.
To buy or view more detailed product information and pricing, please click on the technical datasheet page below:
Coagulation Factor VIII, also known as FVIII and F8, is a member of the multicopper oxidase family. Coagulation Factor VIII is a cofactor for factor IXa which, in the presence of Ca+2 and phospholipids, converts factor X to the activated form Xa. It contains 3 F5/8 type A domains, 2 F5/8 type C domains and 6 plastocyanin-like domains. FVIII is synthesized in the liver, and perhaps in other tissues. It is a coagulation cofactor which circulates bound to von Willebrand factor and is part of the intrinsic coagulation pathway. It is a macromolecular complex composed of two separate entities, one of which, when deficient, results in hemophilia A, and the other, when deficient, results in von Willebrand\'s disease. Hemophilia An is a disorder of blood coagulation characterized by a permanent tendency to hemorrhage. About 50% of patients have severe hemophilia resulting in frequent spontaneous bleeding into joints, muscles and internal organs. Less severe forms are characterized by bleeding after trauma or surgery.
Immunogen: Recombinant Human Coagulation Factor VIII/FVIII/F8 protein
Buffer: This antibody was obtained from a rabbit immunized with purified, recombinant Human Coagulation Factor VIII/FVIII/F8 protein. In general, we may offer more than one antibody to a given target to enable options for the researcher. Available antibodies recognizing F8� are readily searchable from our website. Different antibodies against the same target such as F8� may be optimized or tested for different applications and species. This enables researchers to select the option that may be best for their model system, to screen more than antibody to determine which one may be best for their model system, as well as to use more than one antibody to follow up on and validate their results.